Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 23, 2025, titled "Eugia Pharma receives USFDA approval for Dasatinib Tablets".
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma's subsidiary Eugia Pharma has received approval from the US health regulator (USFDA) for Dasatinib Tablets. Dasatinib is a generic oncology drug commonly used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The approval allows the company to manufacture and market this product in the US market. This adds to Eugia Pharma's growing portfolio of approved generic products in the United States.
This is a positive development for Aurobindo Pharma as it opens up a new revenue stream in the high-value US generic oncology market, potentially strengthening its US business segment.